Literature DB >> 15716465

Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene.

Tim O Lankisch1, Arndt Vogel, Stefan Eilermann, Anette Fiebeler, Britta Krone, Ayse Barut, Michael P Manns, Christian P Strassburg.   

Abstract

UDP glucuronosyltransferases (UGT) detoxify bilirubin and therapeutic drugs, a process influenced by single nucleotide polymorphisms (SNPs) in their structural genes and promoter elements. UGT1A1*28 is a functional UGT promoter polymorphism associated with Gilbert's disease and severe irinotecan toxicity, which also occurs in the absence of UGT1A1*28. The aim of this study was to identify and characterize UGT promoter variants relevant for irinotecan detoxification. Recombinant UGT1A proteins were analyzed for irinotecan metabolite glucuronidation by UGT activity assays. In 427 healthy blood donors and 71 homozygous UGT1A1*28 carriers, the 5'-untranslated region of the UGT1A7 gene locus was studied. An SNP was detected by allelic discrimination and characterized by reporter gene experiments. A novel -57 T--> G SNP with a gene frequency of 0.39 in healthy blood donors was identified in the putative TATA box of the UGT1A7 gene, reducing promoter activity to 30%. It is in linkage dysequilibrium with a variant of the UGT1A7 first exon that is present in the reduced-activity UGT1A7*3 and UGT1A7*4 alleles. Homozygous UGT1A1*28 carriers simultaneously carried this variant in 97%. We identified a novel reduced-function TATA box SNP of the UGT1A7 gene that catalyzes irinotecan metabolite detoxification. Its association with variants of the UGT1A1 promoter and UGT1A7 gene may influence irinotecan metabolism. Our finding emphasizes the importance of combinations of structural and regulatory gene polymorphisms that may be useful as markers of drug toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716465     DOI: 10.1124/mol.104.007146

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

3.  Functional characterization of liver enhancers that regulate drug-associated transporters.

Authors:  M J Kim; P Skewes-Cox; H Fukushima; S Hesselson; S W Yee; L B Ramsey; L Nguyen; J L Eshragh; R A Castro; C C Wen; D Stryke; S J Johns; T E Ferrin; P-Y Kwok; M V Relling; K M Giacomini; D L Kroetz; N Ahituv
Journal:  Clin Pharmacol Ther       Date:  2011-03-02       Impact factor: 6.875

4.  Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

Authors:  Shouji Shimoyama
Journal:  World J Gastrointest Surg       Date:  2010-01-27

5.  Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers.

Authors:  Chonlaphat Sukasem; Chalirmporn Atasilp; Pichai Chansriwong; Montri Chamnanphon; Apichaya Puangpetch; Ekapob Sirachainan
Journal:  J Clin Lab Anal       Date:  2014-12-26       Impact factor: 2.352

6.  UDP-glucuronosyltransferases mediate coffee-associated reduction of liver fibrosis in bile duct ligated humanized transgenic UGT1A mice.

Authors:  Steffen Landerer; Sandra Kalthoff; Christian P Strassburg
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

7.  Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Authors:  Vineetha Koroth Edavana; Ishwori B Dhakal; Suzanne Williams; Rosalind Penney; Gunnar Boysen; Aiwei Yao-Borengasser; Susan Kadlubar
Journal:  Drug Metab Dispos       Date:  2013-01-31       Impact factor: 3.922

Review 8.  Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Christine L H Snozek; Dennis J O'Kane; Alicia Algeciras-Schimnich
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

9.  UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

Authors:  E Martinez-Balibrea; A Abad; A Martínez-Cardús; A Ginés; M Valladares; M Navarro; E Aranda; E Marcuello; M Benavides; B Massutí; A Carrato; L Layos; J L Manzano; V Moreno
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 10.  Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Chandrasekaran Adithan
Journal:  Indian J Med Res       Date:  2014-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.